Trending...
- US Dollar Provides Exceptional Value For Sightseeing Trips To Italy, Havana, Cuba, Delhi, Agra and Jaipur and Barcelona, Spain
- Century 21's The Gene Group Joins PalMar Studios as a Primary Partner on "Triangle Park," a Documentary on the NFL's First-Ever Game
- What You Need to Know on "Opening an IV Therapy Clinic" Podcast Interview to Grow, Start or Expand IV Hydration Therapy Business
Prestigious CDMRP award will advance development of ORP100S as an inhaled treatment for acute and chronic respiratory diseases
SAN DIEGO - PRDelivery -- OrPro Therapeutics, Inc., a San Diego Johnson & Johnson JLABS alumni and 2022 SD CONNECT Cool Company, is pleased to announce that it has been awarded a Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development grant under the Congressionally Directed Medical Research Program (CDMRP) of the US Department of Defense. This $2.147M award entitled "Development of Monothiol Human Thioredoxin-1 (ORP100S) as an Inhaled Treatment for Acute Viral Lung Injury" involves OrPro researchers and collaborators at the Institute for Airway Sciences in the Icahn School of Medicine at Mount Sinai (New York, NY), Lovelace Biomedical (Albuquerque, NM), and KCAS Bioanalytical Services (Olathe, KS). Project advisors include innate immunity opinion leader Dr. Richard Ulevitch, Professor and former Chair of the Department of Immunology at Scripps Research; 3-D stem cell derived human lung organoid pioneer Dr. Ya-Wen Chen at Mount Sinai; and internationally recognized inhalation toxicology expert Dr. Jeffrey Tepper.
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on PR Delivery
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on PR Delivery
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on PR Delivery
- HWS Announces Top 10 Low Cost Vacation Spots
- World's First Walkie-Talkie Bone Conduction Sport Headphones
- Construction Begins on Comprehensive Sedation Dentistry Center in Frederick Maryland
- Kinugawa Onsen Celebrates its 330th Anniversary AND Kawagoe City Celebrates its 100th Anniversary - Both with Fireworks!
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on PR Delivery
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
Source: OrPro Therapeutics
0 Comments
Latest on PR Delivery
- The Data Economics Company and Syzygy Publishing's Chris Ryall announces content partnership
- The Stars Align for Coffee Lovers in North Texas with Opening of Tre Stelle Coffee Co. in North Dallas
- German skin cancer patients join the EPIC-Skin study
- Boston Industrial Solutions, Inc., introduces UV Ink for digital printing equipment
- EVERWILD Music Festival brings big names in reggae-rock to Ohio
- Hamilton County Commissioner and Founder of the Cincinnati Black Music Walk of Fame, Alicia Reece, Led A Star-Studded 2nd Annual Induction Ceremony
- LifeHealth, A New Innovation Transforming Access To Healthcare
- The Fuse Group Announces New FOLKS President Amélie Poitras
- Good Pharma Announces Women's Business Enterprise (WBE) Certification
- Sealion Cargo Launches Crypto Logistics Division at Mining Disrupt 2022
- Universal Solar to Open PV Module Factory in Panama; 400 MW in Orders Already Received
- A New Orlando Advertising Agency With a Nontraditional Business Model is Launched by Industry Veteran Wagner dos Santos
- Sidow Sobrino's New Single and Video Richard's Cumbia are Now Available for Streaming
- TrueDialog Accepted to the Microsoft Power App Platform
- First-ever app connects entertainment professionals with early release
- Vacuum Butt Lift Center Upgrade Their Offerings To Service Clients In Flatiron New York
- Pilsen Art Resurgence featuring Ty Nitz + Friends
- The Boutique Hotel Higashiyama by Kyoto Tokyu Opened July 7, 2022 in the Center of Kyoto
- Dale Sorensen Real Estate sales associate Kathy Hainey lists spectacular Vero Beach Florida pool home
- Tobu Railway to Introduce its Latest N100 Series of Limited Express Spacia X Trains in July 2023